Match!
Maarten Joost IJzerman
University of Twente
429Publications
40H-index
6,366Citations
Publications 429
Newest
#1Michelle M.A. Kip (UT: University of Twente)H-Index: 5
#2Gillian Currie (U of C: University of Calgary)H-Index: 13
Last.Maarten Joost IJzerman (UT: University of Twente)H-Index: 40
view all 11 authors...
Background This study aims to describe current practice in identifying and measuring health care resource use and unit costs in economic evaluations or costing studies of juvenile idiopathic arthritis (JIA).
Source
#1Michelle M.A. Kip (UT: University of Twente)H-Index: 5
#2J. Marjan Hummel (UT: University of Twente)H-Index: 9
Last.Ron Kusters (UT: University of Twente)H-Index: 10
view all 7 authors...
The increasing number of available point-of-care (POC) tests challenges clinicians regarding decisions on which tests to use, how to efficiently use them, and how to interpret the results. Although POC tests may offer benefits in terms of low turn-around-time, improved patient’s satisfaction, and health outcomes, only few are actually used in clinical practice. Therefore, this study aims to identify which criteria are, in general, important in the decision to implement a POC test, and to determi...
2 CitationsSource
#1Deon Lingervelder (UT: University of Twente)
#2Hendrik Koffijberg (UT: University of Twente)H-Index: 22
Last.Maarten Joost IJzerman (UT: University of Twente)H-Index: 40
view all 4 authors...
Objectives: There are numerous point-of-care tests (POCTs) available on the market, but many of these are not used. This study reviewed literature pertaining to the evaluation/usage of POCTs in primary care, to investigate whether outcomes being reported reflect aspects previously demonstrated to be important for general practitioners (GPs) in the decision to implement a POCT in practice. Methods: Scopus and Medline were searched to identify studies that evaluated a POCT in primary care. We iden...
Source
#1Nora Franzen (UT: University of Twente)H-Index: 1
#2Willem H. van Harten (UT: University of Twente)H-Index: 23
Last.Maarten Joost IJzerman (UT: University of Twente)H-Index: 40
view all 6 authors...
Healthcare systems are faced with the challenge of providing innovative treatments, while shouldering high drug costs that pharmaceutical companies justify by the high costs of R&D. An emergent technology that could transform R&D efficiency is organ-on-a-chip. The technology bridges the gap between preclinical testing and human trials through better predictive models, significantly impacting R&D costs. Here, we present an expert survey on the future role of organ-on-a-chip in drug discovery and ...
1 CitationsSource
#1M. van de Ven (UT: University of Twente)
#2Valesca P. Retèl (UT: University of Twente)H-Index: 16
Last.Maarten Joost IJzerman (UT: University of Twente)H-Index: 40
view all 5 authors...
Abstract Objectives Increased emphasis on molecular diagnostics can lead to increased variation in time to treatment (TTT) for patients with stage III and IV non-small cell lung cancer. This article presents the variation in TTT for advanced NSCLC patients observed in Dutch hospitals before the widespread use of immunotherapy. The aim of this article was to explore the variation in TTT between patients, as well as between hospitals. Material and methods Based on the Netherlands Cancer Registry, ...
Source
#1A.M. Sofie Berghuis (UT: University of Twente)H-Index: 3
#2Carolien H.M. van Deurzen (EUR: Erasmus University Rotterdam)H-Index: 23
Last.Maarten Joost IJzerman (UT: University of Twente)H-Index: 40
view all 6 authors...
Purpose The estrogen (ER), progesterone (PR), and HER2 status are essential in guiding treatment decisions in breast cancer patients. In daily life, the ER/PR/HER2 status is expected to be commonly tested twice, i.e., at diagnosis using material from tumor needle biopsies, and after tumor resection using full tumor tissue material. This study explored the discordance of ER/PR/HER2 between tumor needle biopsies and full tumor resection material using real-world patient-level data from Dutch breas...
1 CitationsSource
#1Hui-Li Wong (WEHI: Walter and Eliza Hall Institute of Medical Research)H-Index: 11
#2Koen Degeling (University of Melbourne)
Last.Peter Gibbs (WEHI: Walter and Eliza Hall Institute of Medical Research)H-Index: 45
view all 16 authors...
e18061Background: The wide range of possible combinations and sequences available for mCRC treatment presents a major challenge to clinicians, who need to determine the optimal approach for an indi...
Source
#1Hui-Li WongH-Index: 11
#2K DegelingH-Index: 2
Last.Peter GibbsH-Index: 45
view all 16 authors...
Source
#1Marjolein A. Heuvelmans (UG: University of Groningen)H-Index: 13
#2Marleen Vonder (UG: University of Groningen)H-Index: 3
Last.Matthijs OudkerkH-Index: 68
view all 9 authors...
Lung cancer, chronic obstructive pulmonary disease, and cardiovascular disease are highly prevalent in the general population and expected to cause most deaths by 2050. For these "Big-3," treatment might cure, delay, or stop the progression of disease at a very early stage. Lung nodule growth rate (a biomarker for lung cancer), emphysema/air trapping (a biomarker for chronic obstructive pulmonary disease), and coronary artery calcification (a biomarker for cardiovascular disease) are imaging bio...
1 CitationsSource
#1K DegelingH-Index: 2
#2Hui-Li WongH-Index: 11
Last.Maarten Joost IJzermanH-Index: 40
view all 6 authors...
Source
12345678910